Описание
Ход выполнения
Заболевания
Дата начала КИ
30.05.2018
Дата окончания КИ
05.08.2020
Организация, проводящая КИ
Pfizer
Фаза КИ
II
Цель КИ
This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.
Количество пациентов
20
Источник